ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc (CDT)

0.0747
0.0091
(13.87%)
終了 12月22日 6:00AM
0.0709
-0.0038
(-5.09%)
取引時間後: 9:52AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
0.0709
買値
0.068
売値
0.0709
出来高
19,962,479
0.0619 日の範囲 0.0758
0.0621 52 週間の範囲 6.10
時価総額
前日終値
0.0656
始値
0.0619
最終取引時間
財務取引量
US$ 1,374,568
VWAP
0.068858
平均取引量 (3 か月)
26,681,405
発行済株式数
102,847,973
配当利回り
-
PER
-286.08
1 株当たり利益 (EPS)
-0.06
歳入
-
純利益
-6.06M

Conduit Pharmaceuticals Inc について

Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmun... Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company's licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto's Thyroiditis. The Company's asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto's Thyroiditis (HT) and Graves' disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto's Thyroiditis and Graves' disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI). 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
Conduit Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker CDT. The last closing price for Conduit Pharmaceuticals was US$0.07. Over the last year, Conduit Pharmaceuticals shares have traded in a share price range of US$ 0.0621 to US$ 6.10.

Conduit Pharmaceuticals currently has 102,847,973 shares in issue. The market capitalisation of Conduit Pharmaceuticals is US$6.75 million. Conduit Pharmaceuticals has a price to earnings ratio (PE ratio) of -286.08.

CDT 最新ニュース

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and...

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced...

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital...

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial...

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright...

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656AZD1656, a HK-4...

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor...

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

SAN DIEGO and LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the approval of a...

Conduit Pharmaceuticals to Join Russell 3000® Index

SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (the “Company” or “Conduit"), today announced the Company is set to join the broad-market...

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ: SQFT; SQFTP; SQFTW) (“Presidio” or the “Company”), an internally managed, diversified real estate investment...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.011201-13.64295197380.0821010.08720.0621144338830.07466572CS
4-0.0284-28.60020140990.09930.11890.0621157332080.08615868CS
12-0.0553-43.81933438990.12620.15790.0621266814050.10556276CS
26-1.6191-95.80473372781.691.8050.0621187148130.13323266CS
52-4.4791-98.44175824184.556.10.062195266700.14002336CS
156-12.5291-99.437301587312.612.890.062177694970.1742911CS
260-12.5291-99.437301587312.612.890.062177694970.1742911CS

CDT - Frequently Asked Questions (FAQ)

What is the current Conduit Pharmaceuticals share price?
The current share price of Conduit Pharmaceuticals is US$ 0.0709
How many Conduit Pharmaceuticals shares are in issue?
Conduit Pharmaceuticals has 102,847,973 shares in issue
What is the market cap of Conduit Pharmaceuticals?
The market capitalisation of Conduit Pharmaceuticals is USD 6.75M
What is the 1 year trading range for Conduit Pharmaceuticals share price?
Conduit Pharmaceuticals has traded in the range of US$ 0.0621 to US$ 6.10 during the past year
What is the PE ratio of Conduit Pharmaceuticals?
The price to earnings ratio of Conduit Pharmaceuticals is -286.08
What is the reporting currency for Conduit Pharmaceuticals?
Conduit Pharmaceuticals reports financial results in USD
What is the latest annual profit for Conduit Pharmaceuticals?
The latest annual profit of Conduit Pharmaceuticals is USD -6.06M
What is the registered address of Conduit Pharmaceuticals?
The registered address for Conduit Pharmaceuticals is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Conduit Pharmaceuticals website address?
The website address for Conduit Pharmaceuticals is www.conduitpharma.com
Which industry sector does Conduit Pharmaceuticals operate in?
Conduit Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
MYSZMy Size Inc
US$ 4.2001
(211.12%)
120.01M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
76.64M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
33.95M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.61k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
120.4M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

CDT Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock